VBIO
Valion Bio Inc.

86
Mkt Cap
$2.82M
Volume
368,568.00
52W High
$5.60
52W Low
$0.7217
PE Ratio
-0.09
VBIO Fundamentals
Price
$0.88
Prev Close
$0.9309
Open
$0.97
50D MA
$1.01
Beta
1.24
Avg. Volume
208,475.57
EPS (Annual)
-$7.58
P/B
0.23
Rev/Employee
$0.00
$2.85
Loading...
Loading...
News
all
press releases
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR Platform
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR Platform Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS PR Newswire SAN ANTONIO, May 14, 2026 First Reporting Quarter as Valion Bio Marked by...
PR Newswire·2d ago
News Placeholder
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 PR Newswire SAN ANTONIO, Texas, May 11, 2026 SAN...
PR Newswire·5d ago
News Placeholder
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION VALION BIO RECEIVES FIRST...
PR Newswire·11d ago
News Placeholder
Valion Bio Appoints Melinda Lackey as General Counsel
Valion Bio Appoints Melinda Lackey as General Counsel Valion Bio Appoints Melinda Lackey as General Counsel PR Newswire SAN ANTONIO, May 4, 2026 Seasoned Biopharmaceutical Attorney with Deep IP...
PR Newswire·12d ago
News Placeholder
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME PR Newswire SAN ANTONIO, April 28, 2026...
PR Newswire·18d ago
News Placeholder
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model...
PR Newswire·23d ago
<
...
1
>

Latest VBIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.